Merrill maintains NPS at buy

NPS Pharmaceuticals Inc. was maintained by Merrill Lynch analyst Eric Ende at a buy rating on the company's uneventful fourth-quarter earnings report. Upcoming catalysts include the March 10 PDUFA for Preos and data from the phase 2 trial of teduglutide for Crohn's disease, expected in late February. Shares of the Salt Lake City pharmaceutical company were down 2 cents, or 0.14%, at $13.92 on volume of 549,601 shares versus the three-month running average of 549,416 shares. (Nasdaq: NPSP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.